1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

“Frank” Talk On Drug Pricing: HHS Official Sees Value-Based Pricing As Area Of Common Interest

 
• By Cole Werble

The most likely next step in executive branch action on drug pricing will be testing approaches to value-based pricing in categories where pharmaceutical companies are willing participants. That appears to be the message from an HHS official speaking at a DC policy event.

At a time when the headlines continue to focus on draconian options to control drug prices in the context of Presidential campaign politics, the reality remains that there are few if any viable options to control drug prices in the US—but that there are opportunities for manufacturers to be proactive in testing new pricing models that may prove both economically attractive and politically wise.

The latest example of the disconnect between headline risk and policy substance came at an October 5 Pew event on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access

UK’s Plan To Become World’s Third Top Life Sciences Economy Falls Short, Says ABPI

 
• By Neena Brizmohun

The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.

Spain’s Medicines Shortages Plan Clears Administrative Hurdles For Essential Medicine Manufacturers

 
• By Francesca Bruce

A new plan to tackle medicine shortages proposes to develop a set of incentives for companies to manufacture essential medicines in Spain.

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek

 
• By Neena Brizmohun

Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.